Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 1/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | HCK | P08631 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.33 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.33 |
| ▸ | PRKDC | P78527 | 1/20 | 0.33 |
| ▸ | CBLB | Q13191 | 1/20 | 0.32 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12758842 | 0.80 | OGA (0.48) | OGAKEAP1PIK3CDABL1EGFR | |
| SCHEMBL25894172 | 0.79 | OGA (0.37) | OGAKEAP1PIK3CDABL1EGFR | |
| SCHEMBL19669658 | 0.74 | OGA (0.44) | OGAKEAP1PIK3CDABL1EGFR | |
| SCHEMBL18760560 | 0.74 | OGA (0.38) | OGAKEAP1PIK3CDABL1EGFR | |
| SCHEMBL21240756 | 0.72 | OGA (0.43) | OGAKEAP1PIK3CDABL1EGFR | |
| SCHEMBL13086281 | 0.72 | LMNA (0.34) | — | |
| SCHEMBL21783999 | 0.69 | OGA (0.40) | OGAPIK3CDABL1EGFRHCK | |
| SCHEMBL27419769 | 0.68 | OGA (0.33) | OGAKEAP1PIK3CDABL1EGFR | |
| SCHEMBL19295832 | 0.68 | OGA (0.46) | OGAKEAP1PIK3CDABL1EGFR | |
| SCHEMBL10206386 | 0.68 | OGA (0.46) | OGAKEAP1PIK3CDABL1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230023124-A1 | CANCER TREATMENTS TARGETING CANCER STEM CELLS | REMEDY PLAN, INC. (US) | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230023124-A1 | CANCER TREATMENTS TARGETING CANCER STEM CELLS | MCL1, KIT, GLI1 | OGA 1054/4885KEAP1 144/4885PIK3CD 951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.